What changed for Melanoma
A plain English summary of what recently moved in the public data Voxsanity tracks for Melanoma. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 33 to 34 (+1)
- Trials recruiting worldwide 322 to 325 (+3)
- Trials on record 2,361 to 2,389 (+28)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Melanoma in July 2026. Voxsanity tracks 11 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 181 trials tracked for Melanoma that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04201223 · results posted 18 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04201223) involved families with children, comparing two approaches to sun safety education. One group received a programme called FLARE, while the other received standard sun safety education. A total of 180 parent-child pairs started in the FLARE group and 184 in the standard education group, making roughly 728 participants across both groups at the start. The trial tracked several things over time, including how often children got sunburned, how often they used sunscreen, and what protective clothing they wore. The rep...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03554083 · results posted 4 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 64 people in total across three treatment groups — Arm A (15 people), Arm B (15 people), and Arm C (34 people). All participants started the pre-surgery treatment phase, though some did not go on to complete surgery or the post-surgery treatment phase. The trial was measuring two main things: whether patients had no detectable cancer remaining in the tissue removed during surgery (called a "pathologic complete response"), and how long patients went without their cancer coming back after surgery. The reported data sho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06101134 · results posted 9 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06101134) enrolled 100 people with melanoma — 50 with metastatic melanoma (cancer that had spread) and 50 with resected melanoma (cancer that had been surgically removed). The trial was primarily measuring which route of administration participants preferred for their treatment: a subcutaneous injection (a shot given just under the skin) or an intravenous infusion (a drip through a vein). Participants answered a questionnaire about their experience after their fourth treatment cycle. The reported data shows that when aske...
-
NCT06099782 · results posted 8 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 147 participants in total — 71 in one group and 76 in the other. The trial was designed to compare two ways of giving the cancer medicine pembrolizumab: as a drip into a vein (IV, the standard method) versus as an injection under the skin (subcutaneous, or SC), where it was combined with a second medicine called berahyaluronidase alfa to help the body absorb it. Rather than measuring whether the medicine treated cancer differently, the trial was focused on which method participants themselves *preferred*, and how sati...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05105100 · results posted 6 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05105100) enrolled 25 adults with melanoma, and all 25 completed the study. The trial was not testing whether a treatment worked in the usual sense — instead, it was a biological research study. Its goal was to examine blood samples to find patterns in genes and immune cells (specifically a type called T-cells) that might be linked to how patients respond to a type of cancer immunotherapy known as anti-PD-1 therapy. Researchers analysed these patterns at the start of the study (baseline) and again at 24 weeks. The reporte...
-
NCT03815058 · results posted 30 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03815058) involved people with a type of skin cancer called melanoma. It tested two approaches: one group received a drug called pembrolizumab on its own, and another received pembrolizumab combined with an experimental drug called RO7198457. A small initial safety group of 6 people was enrolled first, followed by a randomised stage where 41 people were assigned to pembrolizumab alone and 84 to the combination. A further 10 people later crossed over to receive the combination treatment after initially being in the pembroli...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05002569 · results posted 8 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05002569) enrolled 1,093 people with melanoma — 547 in Treatment 1 and 546 in Treatment 2. Participants were randomly assigned to one of the two treatment groups. The trial's main goal was to measure "Recurrence Free Survival" (RFS) — that is, how long people went without their cancer coming back or dying from any cause. It also tracked overall survival, how long people lived without the cancer spreading to distant parts of the body, and how participants fared on any follow-up treatment after the trial. The reported data...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01004952 · results posted 7 January 2026
According to the results reported on ClinicalTrials.gov, this trial involved people who had a close family member (such as a parent, sibling, or child) diagnosed with melanoma — a type of skin cancer. These participants are referred to as "first-degree relatives," or FDRs. The study was split into two parts: a first group of 25 people and a second group of 60 people. In total, 94 people started the trial across both groups, and 78 completed it (all 25 in the first group and 53 of the 69 who started in the second group). The trial was looking at how these individuals make decisions about protec...
-
NCT04526899 · results posted 15 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04526899) enrolled 184 people across three groups: 94 participants received a combination of two treatments called BNT111 and cemiplimab, 46 received BNT111 on its own, and 44 received cemiplimab on its own. The trial was looking at how many participants in each group showed a measurable shrinkage or disappearance of their tumours, as assessed by an independent reviewing team who did not know which treatment each person had received. The reported data shows that for the combination group (BNT111 plus cemiplimab), 18% of p...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02706353 · results posted 21 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02706353) involved people with metastatic melanoma (skin cancer that has spread to other parts of the body). It was a two-part study: a Phase 1 part, where small groups of participants received increasing doses of an injected treatment called APX005M (0.1 mg, 0.5 mg, 1 mg, 3 mg, or 10 mg) directly into a tumour, combined with another medicine called pembrolizumab given through a drip; and a Phase 2 part, which expanded enrolment at the chosen dose. In total, the reported data shows 34 people took part across all groups. Th...
-
NCT03901573 · results posted 22 October 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two drugs — NT-I7 and atezolizumab — in people with certain cancers. The study had two phases: an early phase (Phase 1b) testing different dose levels of NT-I7 to assess safety and find an appropriate dose, and a later phase (Phase 2a) looking at how many participants' tumours responded to treatment. In total, 31 people started the trial across all groups — 3 at the lowest dose level, 3 at the second, 7 at the third, 3 at the fourth, and 15 in the Phase 2 group. Not all participants completed the tri...
-
NCT03729596 · results posted 31 July 2025
According to the results reported on ClinicalTrials.gov, this trial tested a drug called vobramitamab duocarmazine across 143 participants in total. Participants were divided into ten groups — five smaller "cohort" groups used in the early dose-finding stage of the trial, and five larger "expansion" groups focused on specific cancer types: prostate cancer (41 people), non-small cell lung cancer (21 people), triple-negative breast cancer (18 people), melanoma (21 people), and head and neck cancer (13 people). The trial was primarily measuring how many participants experienced adverse events (un...
-
NCT05116202 · results posted 18 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 110 people across five treatment groups. The majority (102 participants) were in Cohort 1, which compared four different immunotherapy combinations before surgery for a type of cancer affecting the lymph nodes: a control group receiving nivolumab plus ipilimumab (22 people), tobemstomig alone at 2100 mg (40 people), atezolizumab plus tiragolumab (20 people), and tobemstomig plus tiragolumab (20 people). A smaller Cohort 2 (8 people) received tobemstomig plus tiragolumab for a more advanced form of the disease. The tri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03400332 · results posted 19 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03400332) enrolled a total of 281 participants across two parts. Part 1 tested different doses of an investigational treatment — given either every four weeks (Q4W) or every two weeks (Q2W) — across seven groups ranging from 16 to 63 people per group, including one group that also received two additional medicines called nivolumab and ipilimumab. Part 2 was a randomised comparison involving 62 people who received the investigational treatment combined with nivolumab and ipilimumab, and 60 people who received a placebo (an...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04221438 · results posted 8 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04221438) enrolled just 3 participants, all of whom received the same treatment sequence: medication with encorafenib and binimetinib before surgery, followed by surgery, and then the same medication again after surgery. The trial was primarily looking at whether the tumour was completely gone (no living cancer cells remaining) when surgeons examined the tissue removed during the operation — a measure called pathologic complete response. It also tracked how long participants went without their disease returning, how long t...
-
NCT05061134 · results posted 21 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05061134) looked at two experimental medicines — ceralasertib (used alone or combined with durvalumab) — in people with cancer. The main part of the trial enrolled 100 people in the combination group and 51 in the ceralasertib-alone group. A separate biopsy sub-study enrolled 43 people in the combination group, where researchers took tumour tissue samples to see whether the treatment changed the number of a particular type of immune cell (called CD8+ T-cells) inside the tumour. The trial's two main goals were to measure ho...
-
NCT02799095 · results posted 21 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02799095) enrolled participants with advanced cancers, including melanoma and kidney cancer (renal cell carcinoma, or RCC). The trial tested a drug called nemvaleukin alfa, given alone or combined with another drug called pembrolizumab. It was run in three parts: Part A tested increasing doses of nemvaleukin alfa in 46 people to find a safe dose range; Part B expanded testing at the chosen dose in 47 people with melanoma and 27 people with kidney cancer; and Part C tested the drug in combination with pembrolizumab across s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04526730 · results posted 6 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04526730) enrolled 17 people, all of whom received the neoadjuvant (pre-surgery) treatment being studied. Sixteen of the 17 participants completed the trial, while one did not finish. The trial was measuring several things: whether the cancer had completely disappeared from tissue samples taken at surgery (called a pathologic complete response), how many participants' tumours responded before surgery, how participants fared over the following year in terms of their cancer not returning, whether participants were alive at o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05665595 · results posted 6 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,402 people in total — 701 in each of two groups. One group received a combination of two medicines called pembrolizumab and vibostolimab, while the other group received pembrolizumab alone. The trial was designed to measure how long participants went without their cancer coming back (called "recurrence-free survival"), as well as to track any unwanted medical events (called adverse events) that occurred during the study, including any that led to a participant stopping treatment. The reported data shows that for th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04698187 · results posted 2 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 44 participants, all of whom received a combination of two treatments: CMP-001 and nivolumab. The trial was designed to measure how many participants' tumours shrank or disappeared (called an "objective response"), as well as to track unwanted health events (called adverse events) that occurred during treatment. The reported data shows that none of the 44 participants were recorded as having "completed" the trial in the conventional sense — all 44 were listed under "not completed," which may reflect how the study's en...
-
NCT02437136 · results posted 20 March 2025
According to the results reported on ClinicalTrials.gov, this trial tested a combination of two drugs — entinostat and pembrolizumab — across two stages. The first stage (Phase 1b) involved 22 people and was designed to find an appropriate dose. The second stage (Phase 2) enrolled 185 people across four separate groups (called cohorts), each made up of people with different types of cancer. All Phase 2 participants received entinostat 5 mg weekly combined with pembrolizumab. The main thing the Phase 2 stage was measuring was the "objective response rate" — that is, the proportion of participan...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03997474 · results posted 7 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03997474) enrolled 13 people in total across three groups — 9 participants in Cohort A, 2 in Cohort B, and 2 in Cohort C. The trial was testing a treatment called ATL001 in people with recurrent or metastatic melanoma (a type of skin cancer that had spread or come back). The primary focus was on tracking unwanted medical events (called adverse events) that appeared during treatment, to look at how often they occurred, how serious they were, and whether they were thought to be related to ATL001. The reported data shows that...
-
NCT05297565 · results posted 27 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 14 people across two groups — 6 participants in Arm A and 8 participants in Arm B. The trial was primarily focused on tracking the safety of the study treatments by recording whether participants experienced any unexpected medical events (called adverse events) or more serious medical events (called serious adverse events) during the study period. Five people in Arm A and six people in Arm B completed the trial, with one and two participants respectively not completing it. The reported data shows that in Arm A, all 6...
-
NCT03665597 · results posted 10 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03665597) looked at how the cancer medicine pembrolizumab behaves in the body when given in two different ways: as an injection under the skin (subcutaneous, or "SC") and as a drip into a vein (intravenous, or "IV"). The trial had two main groups. Cohort A included 37 people who were assigned to one of six sequences that rotated between a subcutaneous injection at two different concentrations (130 mg/mL and 165 mg/mL) and an IV drip, so the same participants received different forms of the medicine at different times. Coho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04993677 · results posted 22 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04993677) enrolled 77 people across four groups: 21 with relapsed or treatment-resistant melanoma (skin cancer that had come back or stopped responding to prior treatment), 39 with uveal melanoma (a rarer form of eye-related melanoma), 9 with a type of lung cancer (non-small cell lung cancer, or NSCLC) where a protein marker called PD-L1 was present at low-to-moderate levels, and 8 with the same lung cancer type but where that marker was barely detectable. The trial's main goal was to measure how many participants' tumours...
-
NCT04382664 · results posted 14 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04382664) enrolled 156 people in total — 78 in a group receiving a vaccine called UV1 combined with two immunotherapy medicines (nivolumab and ipilimumab), and 78 in a group receiving just the two immunotherapy medicines without the vaccine. The trial was primarily looking at something called **progression-free survival (PFS)** — that is, how long participants went without their cancer getting worse or spreading, as assessed by an independent team reviewing scans. Several secondary things were also planned to be measured,...
-
NCT04157517 · results posted 27 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04157517) tested a drug called modakafusp alfa — alone at various doses, and later combined with another drug called pembrolizumab — in people with solid tumour cancers. In total, 45 participants were enrolled across all groups: small groups of 3–6 people tested increasing doses of modakafusp alfa in a Phase 1b stage, 3 people took part in a Phase 2 safety lead-in combining both drugs, and a further 21 people were enrolled across two expansion groups in Phase 2 (9 in Cohort I and 12 in Cohort II). A tenth planned group (Co...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03092453 · results posted 24 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03092453) tested a specialised vaccine called a Mature Dendritic Cell (DC) vaccine in people with cancer. Dendritic cells are a type of immune cell, and the vaccine was designed to try to train the body's immune system to recognise cancer. Five people started the trial, three completed it, and two did not finish. The trial was measuring whether the vaccine produced a specific immune response in the blood, how safe and tolerable it was, and how participants' cancer responded over time. The reported data shows that for the...
-
NCT03341143 · results posted 30 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 participants, all of whom completed the study. Every participant received the same combination: a faecal microbiota transplant (FMT) — a procedure where gut bacteria from a donor are transferred to a patient — together with a cancer immunotherapy drug called pembrolizumab. The trial was primarily measuring the "objective response rate," meaning how many participants showed a meaningful shrinkage of their cancer according to standard imaging criteria. The reported data shows that, for the primary measure, 2 partici...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01436656 · results posted 28 October 2024
According to the results reported on ClinicalTrials.gov, this trial tested a drug called encorafenib in people with advanced cancers, primarily melanoma and metastatic colorectal cancer. The trial had two main stages: a dose escalation phase (where researchers tested increasing amounts of the drug to find an appropriate dose) and a dose expansion phase (where selected doses were tested in larger groups). In total, 54 participants took part in the dose escalation stage across 11 different dose groups, and 53 participants took part in the dose expansion stage across 7 groups. The trial was prima...
See all 181 reported results for Melanoma
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, melanoma currently attracts a very large amount of public research investment from the United States, and that level of support has remained broadly steady over recent time. For patients, this signals that melanoma is a well-established research priority with sustained scientific attention behind it. A stable and substantial funding base generally means researchers a...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.